Related Experiment Video
Updated: May 11, 2025

Knee Arthrocentesis in Adults
Published on: February 25, 2022
Characterising infusion/injection-related reactions in patients with rheumatoid arthritis treated with biologic
Ji-Won Kim1, Sun-Kyung Lee2, Kichul Shin3
1Department of Rheumatology, Ajou University School of Medicine, Suwon, Republic of Korea.
Objectives:
Biologic disease-modifying anti-rheumatic drugs (bDMARDs) have transformed the management of rheumatoid arthritis (RA), but their efficacy can be limited by infusion/injection-related reactions (IRRs). This study investigated demographic and clinical factors associated with IRRs in patients with RA using data from the Korean College of Rheumatology Biologics & Targeted Therapy (KOBIO) Registry.
Methods:
We analysed 1,832 patients with RA, categorising them into IRR and non-IRR groups. Demographic, disease characteristics, and treatment histories were compared. A Sankey plot visualised bDMARD switching patterns, and multivariable logistic regression identified IRR-independent predictors.
Results:
IRRs occurred in 9.7% of patients and were significantly associated with younger age (mean 49.9 vs. 54.9 years; OR=1.793, p=0.014), secondary Sjögren's syndrome (OR=2.175, p=0.035), and prior leflunomide use (OR=1.497, p=0.015). Abatacept (OR=0.263, p<0.001), tocilizumab (OR=0.419, p<0.001), and golimumab (OR=0.345, p=0.006) were associated with reduced IRR risk compared to infliximab. Following IRRs, use of etanercept, infliximab, and adalimumab declined, while tocilizumab and Janus kinase (JAK) inhibitors increased.
Conclusions:
IRRs are common among RA patients receiving bDMARDs, particularly in younger individuals or those with prior leflunomide use. Abatacept, tocilizumab, and JAK inhibitors represent safer alternatives, underscoring the need for individualised treatment strategies.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Allergic Drug Reactions
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Routes of Drug Administration: Parenteral
The intravenous route (IV) of drug administration can be further categorized into two types. The bolus injection administers the entire dose rapidly, while an intravenous infusion slowly delivers smaller doses steadily.
The IV route is often...

